comparemela.com

Latest Breaking News On - Asco recommendations - Page 1 : comparemela.com

Testing for ESR1 Mutations in Breast Cancer

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Erical mayerKevin kalinskyBreast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsBiomarker testingEsr1 testingAsco recommendationsCirculating tumor dna

Overcoming Challenges in Biomarker Testing in Breast Cancer

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

Breast cancerBiomarker testingHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsEsr1 testingAsco recommendationsCirculating tumor dna

ASCO Recommends Trilaciclib in Extensive-Stage Small Cell Lung Cancer in Guideline Update

In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.

United statesRaj malikHealth cancer care ontario guidelineAmerican society of clinical oncologyAmerican societyClinical oncologyOntario healthCancer care ontarioSmall cell lung cancerAsco recommendations

vimarsana © 2020. All Rights Reserved.